Veru (VERU) Total Current Liabilities : $16.63 Mil (As of Dec. 2023)

View and export this data going back to 1990. Start your Free Trial

What is Veru Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Veru's total current liabilities for the quarter that ended in Dec. 2023 was $16.63

Veru Total Current Liabilities Historical Data

The historical data trend for Veru's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru Total Current Liabilities Chart

Veru Annual Data

Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23

Total Current Liabilities

Get a 7-Day Free Trial 14.02 14.73 15.77 38.71 17.81

Veru Quarterly Data

Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23

Total Current Liabilities Get a 7-Day Free Trial 40.08 39.26 27.69 17.81 16.63

Veru Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Veru's Total Current Liabilities for the fiscal year that ended in Sep. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 14.919 + 1.901

+ Other Current Liabilities + Current Deferred Liabilities

= 0.991 + 0

= 17.81

Veru's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 12.602 + 1.869

+ Other Current Liabilities + Current Deferred Liabilities

= 2.154 + 0

= 16.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Veru Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of Veru's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Veru (VERU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (NAS:VERU) » Definitions » Total Current Liabilities

Comparable Companies

CVM ATHA VANI RZLT DMAC PROK RVPH RNAC VINC ANIX OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX

Traded in Other Exchanges

FMW:Germany

Address

2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127

Website

https://www.verupharma.com

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.

Executives

Mario Eisenberger director 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654

Lucy Lu director THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137

Harry Fisch director, 10 percent owner 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654

Grace Hyun director 48 NW 25TH STREET, SUITE 102, MIAMI FL 33127

Mitchell Shuster Steiner director, 10 percent owner, officer: President and CEO 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103

K Gary Barnette officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137

Michele Greco officer: VP and CFO 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60654

Jesus Socorro director 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137

Todd Charles T Jr officer: CEO of FHC Division 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137

Michael L Rankowitz director 2500 LAKE COOK ROAD, RIVERWOODS IL 60015

Robert Getzenberg officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137

Elgar Peerschke director 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654

Daniel Haines officer: CFO and COO 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654

David R Bethune director THE FEMALE HEALTH COMPANY, 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60610

O B Parrish director, officer: Chairman/Chief Exec. Officer

Veru (VERU) Headlines

From GuruFocus

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Veru Inc. - VERU
By PRNewswire • 11-19-2023

Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023
By Marketwired • 09-20-2023

Veru Inc.'s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants
By sperokesalga sperokesalga • 06-21-2023

VERU DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Veru Inc. and Encourages Investors to Contact the Firm
By Business Wire Business Wire • 02-02-2023

VERU LAWSUIT ALERT: Levi & Korsinsky Notifies Veru Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
By PRNewswire PRNewswire • 02-02-2023

VERU ALERT: Bragar Eagel & Squire, P.C. is Investigating Veru Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
By Business Wire • 12-15-2023

Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board
By sperokesalga sperokesalga • 06-01-2023

Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Veru Inc. (VERU) Investors of Class Action and to Actively Participate
By Business Wire Business Wire • 02-06-2023

VERU INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Veru Inc. - VERU
By Business Wire • 10-16-2023

VERU 3-DAY DEADLINE ALERT: Hagens Berman Encourages Veru Inc. (VERU) Investors with Significant Losses to Contact Firm's Attorneys Before Feb. 6th Deadline in Securities Class Action
By Stock market mentor Stock market mentor • 02-03-2023

Veru Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Liabilities	Get a 7-Day Free Trial															40.08	39.26	27.69	17.81	16.63

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	14.919	+	1.901
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	0.991	+	0
	=	17.81

Mario Eisenberger	director	515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Lucy Lu	director	THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Harry Fisch	director, 10 percent owner	515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Grace Hyun	director	48 NW 25TH STREET, SUITE 102, MIAMI FL 33127
Mitchell Shuster Steiner	director, 10 percent owner, officer: President and CEO	175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
K Gary Barnette	officer: Chief Scientific Officer	4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michele Greco	officer: VP and CFO	515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60654
Jesus Socorro	director	4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Todd Charles T Jr	officer: CEO of FHC Division	4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michael L Rankowitz	director	2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Robert Getzenberg	officer: Chief Scientific Officer	4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Elgar Peerschke	director	515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Daniel Haines	officer: CFO and COO	515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
David R Bethune	director	THE FEMALE HEALTH COMPANY, 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60610
O B Parrish	director, officer: Chairman/Chief Exec. Officer